OXFORD, United Kingdom, June 21, 2023 Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical t.
Vaccitech, a biopharmaceutical company, has created a vaccine named VTP-300. They are currently showcasing positive initial results through a poster presentation at the ongoing European Association for the Study of the Liver (EASL) Congress 2023.
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.